
Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>



































• Screen for ligands or agonist antibodies that can bind and activate CD40.


Expression analysis of human CD40 on Human CD40 (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human CD40 (Luc) HEK293 Reporter Cell or negative control cell using PE-labeled anti-human CD40 antibody.

Agonistic activity analysis of anti-human CD40 antibody.
This reporter cell was incubated with serial dilutions of antibodies in the presence of CHO or CHO/CD32b. Sotigalimab could depend on CD32b-mediated crosslinking to strengthen CD40 signaling. The EC50 of Sotigalimab in the presence of CHO/CD32b was approximately 0.079 μg/mL.

Inhibition of human CD40 ligand protein-induced reporter activity by anti-human CD40 ligand neutralizing antibody.
This reporter cell was incubated with serial dilutions of antibodies in the presence of human CD40 ligand protein with a final concentration of 0.1 μg/mL. The EC50 of anti-human CD40 ligand neutralizing antibody (Frexalimab) was approximately 0.26 μg/mL.

Response to anti-human CD40 antibody (RLU).
The Human CD40 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of anti-human CD40 antibody. The EC50 was approximately 0.096 μg/mL.

Response to anti-human CD40 antibody (FOLD).
The Human CD40 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of anti-human CD40 antibody. The max induction fold was approximately 14.

Response to human CD40 ligand protein (RLU).
The Human CD40 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human CD40 ligand protein. The EC50 was approximately 0.024 μg/mL.

Response to human CD40 ligand protein (FOLD).
The Human CD40 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human CD40 ligand protein. The max induction fold was approximately 9.16.

Passage stability analysis by Signaling Bioassay.
The continuously growing Human CD40 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of anti-human CD40 antibody. Anti-human CD40 antibody stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 6-22.
Please contact us if you are interested in related cell pool service.
BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
| English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|
| English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Anti-CD40 ChiLob7/4 (BioNTech) | Phase 2 Clinical | Biontech Se | Head and Neck Neoplasms; Pancreatic Neoplasms | Details | |
| BSI-038 | BSI-038 | Phase 1 Clinical | Boaoxin Biotechnology(Nanjing) Co Ltd | Solid tumours | Details |
| KPL-404 | KPL-404 | Kiniksa Pharmaceuticals Ltd | Details | ||
| MIL-97 | MIL-97 | Phase 1 Clinical | Beijing Mabworks Biotech Co Ltd | Solid tumours | Details |
| TQB-2916 | TQB2916; TQB-2916 | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Neoplasms | Details |
| Ravagalimab | ABBV-323; PR-1629977 | Abbvie Inc | Details | ||
| MEDI-5083 | MEDI-5083 | Astrazeneca Plc, Medimmune | Details | ||
| ABBV-428 | ABBV-428; ABBV428 | Abbvie Inc | Details | ||
| NJA-730 | NJA-730; NJA-730a; NJA-730b | Phase 1 Clinical | Napajen Pharma | Autoimmune Diseases | Details |
| HPV CD40 HVac | HPV CD40 HVac | Clinical | LinKinVax | Papillomavirus Infections | Details |
| SHR-1704 | SHR-1704 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Neoplasms | Details |
| IMB-071703 | IMB071703; IMB-071703 | Phase 1 Clinical | Beijng Immunoah Pharma Tech Co Ltd | Solid tumours | Details |
| BI-655064 | BI-655064 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Purpura, Thrombocytopenic, Idiopathic; Arthritis, Rheumatoid; Lupus Nephritis | Details |
| 2141-V11 | 2141-V11 | Phase 1 Clinical | Darell Bigner | Ganglioglioma; Urinary Bladder Neoplasms; Glioma | Details |
| Bleselumab | 4D-11; ASKP-1240 | Phase 2 Clinical | Kyowa Hakko Kogyo Co Ltd | Rejection of renal transplantation; Rejection of organ transplantation; Psoriasis; Glomerulosclerosis, Focal Segmental | Details |
| Autologous IL2 and CD40 ligand-expressing tumor cells (Baylor College of Medicine) | Phase 1 Clinical | Baylor College Of Medicine | Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
| CD40.HIVRI.Env Vaccine | Phase 1 Clinical | Anrs | HIV Infections | Details | |
| SL-172154 | SL-172154 | Phase 1 Clinical | Shattuck Labs Inc | Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Myelodysplastic Syndromes; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms | Details |
| LVGN-7409 | LVGN7409; LVGN-7409 | Phase 1 Clinical | Lyvgen Biopharma(HK)Ltd | Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Papillomavirus Infections; Uveal melanoma; Sarcoma; Neoplasm Metastasis; Carcinoma, Hepatocellular | Details |
| Mitazalimab | ADC-1013; JNJ-7107; JNJ-64457107 | Phase 2 Clinical | Alligator Bioscience Ab | Solid tumours; Neoplasms; Carcinoma, Pancreatic Ductal | Details |
| Giloralimab | ABBV-927 | Phase 2 Clinical | Abbvie Inc | Head and Neck Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| RO-7300490 | RO-7300490; RG-6189 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Neoplasms | Details |
| Cifurtilimab | SEA-CD40 | Phase 2 Clinical | Seattle Genetics Inc | Lymphoma, B-Cell; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Neoplasms, Squamous Cell; Pancreatic Neoplasms; Lymphoma, Follicular; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Lymphoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
| Iscalimab | CFZ-533; NVP-CFZ533; OM11-62-MF | Phase 2 Clinical | Novartis Pharma Ag | Diabetes Mellitus, Type 1; Rejection of renal transplantation; Myasthenia Gravis; Rejection of liver transplantation; Arthritis, Rheumatoid; Sjogren's Syndrome; Lupus Nephritis; Lupus Erythematosus, Systemic; Graves Disease; Sjogren-Larsson Syndrome; Hidradenitis Suppurativa | Details |
| Sotigalimab | APX-005M; EPI-0050; APX-005 | Phase 2 Clinical | Epitomics Inc | Glioblastoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Glioma; Lung Neoplasms; Astrocytoma; Sarcoma; Microsatellite Instability; Central Nervous System Neoplasms; Head and Neck Neoplasms; Pancreatic Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Medulloblastoma; Ependymoma | Details |
| Inezetamab | AMG-994 | Phase 1 Clinical | Amgen Inc | Solid tumours; Neoplasms | Details |
| Tecaginlimab | BNT-312; GEN-1042 | Phase 2 Clinical | Genmab A/S | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Peripheral Nervous System Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| CDX-1140 | CDX-1140 | Phase 2 Clinical | Celldex Therapeutics | Uveal melanoma; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Non-Small-Cell Lung; Melanoma; Waldenstrom Macroglobulinemia; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Lung Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Lymphoma, Follicular; Cholangiocarcinoma; Lymphoma, Mantle-Cell; Breast Neoplasms; Urinary Bladder Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Pancreatic Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma; Lymphoma, B-Cell, Marginal Zone; Head and Neck Neoplasms; Ovarian Neoplasms; Liver Neoplasms; Lymphoma, B-Cell | Details |
| YH-003 | YH-003; YH003 | Phase 2 Clinical | Eucure Pharmaceutical Technology (Beijing) Co Ltd | Solid tumours; Pancreatic Neoplasms; Neoplasms; Carcinoma, Pancreatic Ductal; Melanoma | Details |
| CD40L-GVAX | GM.CD40L; CD40L-GVAX; GM-CSF/CD40L; hCD40L/hGM-CSF | Phase 2 Clinical | University Of South Florida | Leukemia; Adenocarcinoma of Lung; Myelodysplastic Syndromes; Lung Neoplasms; Melanoma; Adenocarcinoma | Details |
This web search service is supported by Google Inc.




